Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating solid growth across its key markets.

Financial Highlights

Sun Pharma reported strong financial metrics for Q1FY26:

The company's reported net profit decreased compared to Rs. 28,356.00 million in Q1FY25.

Revenue Growth and Market Performance

Sun Pharma's performance was particularly strong in the Indian market, with formulation sales rising by 13.9% to Rs. 47,211.00 million, accounting for 34.2% of total consolidated sales.

Sun Pharma has further solidified its position as the market leader in India, maintaining its No. 1 position with an 8.3% market share in the Indian pharmaceutical market.

Global Performance

The company's global presence continued to expand, with notable growth in various international markets:

• US formulation sales reached US$ 473.00 million, up 1.4%, contributing 29.3% to total consolidated sales.
• Global Innovative Medicines sales grew by 16.9% to US$ 311.00 million, representing a significant portion of quarterly sales.

Exceptional Charges and Board Restructuring

The company faced exceptional charges of Rs. 8,180.00 million, including:

• Rs. 2,876.40 million for discontinuation of SCD-044 development work
• Rs. 5,303.60 million related to a legal settlement

The Board approved significant changes to committee compositions:

• Mr. Dilip Shanghvi, Mr. Aalok Shanghvi, and Ms. Vidhi Shanghvi received new appointments across various committees
• Mr. Sudhir Valia will cease membership upon retirement at the 33rd Annual General Meeting

Product Pipeline and Market Developments

Sun Pharma continues to strengthen its product portfolio:

• The company launched the dermatology drug LEQSELVI in the US market, offering a new treatment option for patients with severe alopecia areata.
• This launch augments Sun Pharma's portfolio in dermatology and adds a growth engine to its Innovative Medicines business.

Looking Ahead

With its strong performance across key markets, continued focus on R&D, and expansion of its Innovative Medicines portfolio, Sun Pharmaceutical Industries Limited appears well-positioned for sustained growth in the coming quarters. The company's leadership in the Indian market and growing presence in international markets provide a solid foundation for future success in the global pharmaceutical industry.

Sun Pharmaceutical Industries Limited has announced a significant breakthrough in its drug development pipeline for psoriatic arthritis. The company's Phase 3 clinical trials for Tildrakizumab 100 mg, marketed as ILUMYA®, have successfully met their primary endpoint in the treatment of active psoriatic arthritis.

Trial Results

The INSPIRE-1 and INSPIRE-2 studies, both global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials, evaluated the efficacy and safety of Tildrakizumab 100 mg in adult patients with active psoriatic arthritis. Key findings include:

• Both studies achieved their primary endpoint, with a statistically significant improvement in ACR20 response rates at Week 24 compared to placebo (p < 0.05).
• The safety profile was consistent with the known safety profile of ILUMYA, with no new safety signals identified.
• Over 800 adult patients participated in the trials, conducted across clinical sites in the US, Europe, and Asia.

Study Design

The trials had distinct patient populations:

• INSPIRE-1: Enrolled patients with prior exposure to an anti-TNF agent
• INSPIRE-2: Enrolled anti-TNF naïve patients

Patients received either Tildrakizumab 100 mg or placebo, with the active drug administered at Week 0 and then every 12 weeks. This differs from the dosing schedule used in chronic plaque psoriasis trials, which included doses at Week 0, Week 4, and then every 12 weeks.

Implications for Psoriatic Arthritis Treatment

Dr. Marek Honczarenko, Senior Vice President and Head of Global Specialty Development at Sun Pharma, expressed enthusiasm about the results: "These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis."

Psoriatic arthritis, a chronic immune-related disease affecting approximately 1 in 3 people living with psoriasis, causes swelling, pain, and stiffness in joints and entheses. The positive results from these trials suggest that ILUMYA could potentially offer a new treatment option for the estimated 2.4 million Americans living with this condition.

Regulatory Outlook

While ILUMYA is currently approved for the treatment of moderate-to-severe plaque psoriasis in adults, its use in psoriatic arthritis is not yet approved. Sun Pharma plans to use these results to support potential regulatory submissions for ILUMYA in the treatment of active psoriatic arthritis in the US.

The company plans to present detailed findings from the INSPIRE studies at upcoming medical conferences and publish them in a peer-reviewed medical journal.

As Sun Pharma continues to expand its specialty portfolio, which currently accounts for about 20% of company sales, the success of these trials marks a significant step forward in addressing the unmet needs of patients with psoriatic arthritis.

Disclaimer: ILUMYA® (tildrakizumab-asmn) is currently only approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Its use in psoriatic arthritis is investigational and not approved by regulatory authorities.